MEDOLLA, Italië–(BUSINESS WIRE)– Eurosets, een bedrijf gevestigd in Medolla (Italië), leider in de ontwikkeling, productie en commercialisering van geavanceerde medische hulpmiddelen, kondigt de eerste patiënt aan die is behandeld met Colibrì, het lichtste extracorporaal life support (ECLS) dat beschikbaar is op de markt.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20221214005502/en/

Colibrì ontving de CE-markering in oktober 2022 en vult het ECLS-portfolio van Eurosets aan en breidt het uit met als doel tijdelijke ondersteuning te bieden aan patiënten die lijden aan ventrikel falen, hartstilstand of ademhaling falen in een groot aantal verschillende toepassingen, waaronder extracorporale membraan oxygenatie (ECMO), extracorporale cardiopulmonale reanimatie (E-CPR) en mechanische ondersteuning van de bloedsomloop (MCS).

Eurosets Announces First Patient Treated With Colibrì, the Lightest Extracorporeal Life Support System

MEDOLLA, Italy–(BUSINESS WIRE)– Eurosets, a company based in Medolla (Italy) leader in the development, production and commercialization of advanced medical devices, announces the first patient treated with Colibrì, the lightest extracorporeal life support (ECLS) system available in the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005502/en/

Colibrì in the operating room (Photo: Eurosets)

Colibrì received CE-Mark in October 2022 and complements and expands Eurosets ECLS portfolio with the objective to provide temporary support to patients suffering from ventricular failure, cardiac arrest or respiratory failure in a variety of different applications, including extracorporeal membrane oxygenation (ECMO), extracorporeal cardiopulmonary resuscitation (E-CPR) and mechanical circulatory support (MCS).

The first clinical procedure using Colibrì was performed by a team led by Pr Philippe Gaudard, head of the ICU department at the Arnaud de Villeneuve university Hospital of Montpellier, France. The patient was supported on VA-ECMO and successfully weaned after few days of treatment. “I truly believe that Colibrì has the potential to become the new standard of care for ECLS – said Dr. Gaudard –. Colibrì, with its lightweight design, ensures that ECLS can be delivered by the specialised mobile ECMO team whenever and wherever is needed and, through its unique features, allows us to initiate ECMO therapy in a safe, easy and reproducible way with advanced monitoring”.

Featuring a fully magnetic-levitating centrifugal pump that covers adult, paediatric and new-born patients, a series of advanced monitoring capabilities and a complete integration with ECMOLife, Colibrì is the lightest device available in the market. The breakthrough device developed by Eurosets is also the only one equipped with a wi-fi connection that allows innovative remote monitoring, thereby ensuring greater patient safety and easier management for healthcare professionals. A set of unique transport accessories, designed to perform ECLS even in the most difficult scenarios, makes Colibrì the only device available in the market truly able to perform ECLS treatments everywhere there is a life to save.

“We are proud to launch Colibrì, an innovative system that complements our ECLS offering – said Antonio Petralia, CEO and Executive Vice President of Eurosets – Our vision is to reimagine ECLS treatments while responding to diverse medical needs through meaningful innovation and Colibrì is fully in line with these core beliefs”.

Colibrì is currently being introduced in selected European centers as part of a controlled launch, after which a full international commercial release will follow upon achievement of local approvals.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005502/en/

Contacts

Eurosets Press Office

ilenia.franchi@elettrapr.it
+39-393-9079914